These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 30970266)
21. Inverse agonist activity of sarpogrelate, a selective 5-HT2A-receptor antagonist, at the constitutively active human 5-HT2A receptor. Muntasir HA; Bhuiyan MA; Ishiguro M; Ozaki M; Nagatomo T J Pharmacol Sci; 2006 Oct; 102(2):189-95. PubMed ID: 17031071 [TBL] [Abstract][Full Text] [Related]
22. Rodent data and general hypothesis: antipsychotic action exerted through 5-Ht2A receptor antagonism is dependent on increased serotonergic tone. Martin P; Waters N; Schmidt CJ; Carlsson A; Carlsson ML J Neural Transm (Vienna); 1998; 105(4-5):365-96. PubMed ID: 9720968 [TBL] [Abstract][Full Text] [Related]
27. In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain. Bortolozzi A; Díaz-Mataix L; Toth M; Celada P; Artigas F Psychopharmacology (Berl); 2007 Apr; 191(3):745-58. PubMed ID: 17265076 [TBL] [Abstract][Full Text] [Related]
28. Use of LC/MS to assess brain tracer distribution in preclinical, in vivo receptor occupancy studies: dopamine D2, serotonin 2A and NK-1 receptors as examples. Chernet E; Martin LJ; Li D; Need AB; Barth VN; Rash KS; Phebus LA Life Sci; 2005 Dec; 78(4):340-6. PubMed ID: 16139310 [TBL] [Abstract][Full Text] [Related]
32. Conventional and Novel Pharmacological Approaches to Treat Dopamine-Related Disorders: Focus on Parkinson's Disease and Schizophrenia. Perez de la Mora M; Hernandez-Mondragon C; Crespo-Ramirez M; Rejon-Orantes J; Borroto-Escuela DO; Fuxe K Neuroscience; 2020 Jul; 439():301-318. PubMed ID: 31349007 [TBL] [Abstract][Full Text] [Related]
33. In vitro and in vivo characterization of the dopamine D4 receptor, serotonin 5-HT2A receptor and alpha-1 adrenoceptor antagonist (R)-(+)-2-amino-4-(4-fluorophenyl)-5-[1-[4-(4-fluorophenyl)-4-oxobutyl] pyrrolidin-3-yl]thiazole (NRA0045). Okuyama S; Chaki S; Yoshikawa R; Suzuki Y; Ogawa S; Imagawa Y; Kawashima N; Ikeda Y; Kumagai T; Nakazato A; Nagamine M; Tomisawa K J Pharmacol Exp Ther; 1997 Jul; 282(1):56-63. PubMed ID: 9223539 [TBL] [Abstract][Full Text] [Related]
34. 5-HT2 receptor regulation of acetylcholine release induced by dopaminergic stimulation in rat striatal slices. Ramírez MJ; Cenarruzabeitia E; Lasheras B; Del Rio J Brain Res; 1997 May; 757(1):17-23. PubMed ID: 9200494 [TBL] [Abstract][Full Text] [Related]
35. Atypical antipsychotics and inverse agonism at 5-HT2 receptors. Sullivan LC; Clarke WP; Berg KA Curr Pharm Des; 2015; 21(26):3732-8. PubMed ID: 26044975 [TBL] [Abstract][Full Text] [Related]
36. In vitro assays for the functional characterization of (psychedelic) substances at the serotonin receptor 5-HT Pottie E; Stove CP J Neurochem; 2022 Jul; 162(1):39-59. PubMed ID: 34978711 [TBL] [Abstract][Full Text] [Related]
37. Effects of quipazine and m-chlorophenylbiguanide (m-CPBG) on temporal differentiation: evidence for the involvement of 5-HT2A but not 5-HT3 receptors in interval timing behaviour. Body S; Asgari K; Rickard JF; Zhang Z; Fone KC; Bradshaw CM; Szabadi E Psychopharmacology (Berl); 2005 Sep; 181(2):289-98. PubMed ID: 15864559 [TBL] [Abstract][Full Text] [Related]
38. Effects of olanzapine and betahistine co-treatment on serotonin transporter, 5-HT2A and dopamine D2 receptor binding density. Lian J; Huang XF; Pai N; Deng C Prog Neuropsychopharmacol Biol Psychiatry; 2013 Dec; 47():62-8. PubMed ID: 23994047 [TBL] [Abstract][Full Text] [Related]
39. Design of novel dopamine D Zhang C; Li Q; Meng L; Ren Y J Biomol Struct Dyn; 2020 Feb; 38(3):860-885. PubMed ID: 30916624 [TBL] [Abstract][Full Text] [Related]
40. Understanding the Role of Serotonin in Female Hypoactive Sexual Desire Disorder and Treatment Options. Croft HA J Sex Med; 2017 Dec; 14(12):1575-1584. PubMed ID: 29198512 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]